Skip to main content
Spyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc. — Investor Relations & Filings

Ticker · SYRE ISIN · US00773J1034 LEI · 52990017AIJPRH3HQH40 US Manufacturing
Open in API
Filings indexed 740 across all filing types
Latest filing 2020-12-01 Regulatory Filings
Country US United States of America
Listing US SYRE

About Spyre Therapeutics, Inc.

https://spyre.com/

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for patients with inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's approach involves engineering novel antibodies with prolonged activity in the body, which allows for less frequent dosing. Its pipeline targets validated biological mechanisms and explores the use of these antibodies as both monotherapies and in rational combination therapies. Spyre aims to provide treatment options for various gastrointestinal and rheumatic diseases that offer the potential for enhanced efficacy and greater convenience.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content includes an announcement about the FDA granting Rare Pediatric Disease Designation to a drug candidate and an update on market estimates. There are no financial statements or detailed financial data presented. The document is not a full annual or quarterly report, nor is it an earnings release or management discussion. It is an event announcement about regulatory and business developments. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-12-01 English
10-Q
Interim / Quarterly Report Q3 2020
2020-11-05 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 5, 2020, reporting the financial results for the quarter ended September 30, 2020. It specifically states that it includes a press release announcing quarterly financial results. The document is relatively short (3722 characters) and the main content is a press release attached as an exhibit. The text explicitly mentions that the information is not "filed" for certain regulatory purposes and is a press release, which aligns with an Earnings Release (ER) rather than a full Interim/Quarterly Report (IR). The document does not contain detailed financial statements or substantive financial data itself but announces the earnings results. Therefore, the appropriate classification is Earnings Release (ER).
2020-11-05 English
SCHEDULE 13G
Major Shareholding Notification
2020-10-26 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content focuses on an update regarding the enrollment completion timeline of a Phase 3 clinical trial and the impact of COVID-19 on the trial's progress. There are no financial statements or detailed financial analysis present, nor is this a full annual or quarterly report. The document is not a transcript, proxy, or governance report. It is an event update about clinical trial progress, which fits the nature of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like earnings release or management report. The document length is about 5518 characters, which is sufficient for a substantive announcement but does not contain financial data or detailed report content. Therefore, the best classification is Regulatory Filings (RNS).
2020-09-14 English
10-Q
Interim / Quarterly Report Q2 2020
2020-08-10 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.